Molecularly targeted agents: Their promise as cancer chemopreventive interventions

European Journal of Cancer

Volumn 41, Issue 13, 2005, Pages 2003-2015

  Thiery Vuillemin, A ^a,b   Nguyen, T ^a,b   Pivot, X ^b   Spano, J P ^c   Dufresnne, A ^b   Soria, J C ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Chemoprevention; Targeted agents; Trials

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ADVEXIN; BEVACIZUMAB; CETUXIMAB; ERLOTINIB; EVEROLIMUS; FLAVOPIRIDOL; GEFITINIB; IMATINIB; ISIS 3521; LONAFARNIB; OBLIMERSEN; PRINOMASTAT; ROSCOVITINE; SORAFENIB; SUNITINIB; SURVIVIN; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB;

CARCINOGENESIS; CELL CYCLE; CHEMOPROPHYLAXIS; DNA MODIFICATION; HUMAN; MOLECULAR GENETICS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 27644572585     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.06.005     Document Type: Article

References (162)

1. Hong Wk, Sporn MB. Recent advances in chemoprevention of cancer. Science 1997, 278, 1073-1077.
2. Bartsch H, Petruzzelli S, De Flora S, et al. Carcinogen metabolism in human lung tissues and the effect of tobacco smoking: results from a case-control multicenter study on lung cancer patients. Environ Health Prospect 1992, 98, 119-124.
3. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratifies squamous epithelium: clinical implications of multicentric origin. Cancer 1953, 6, 963-968.
4. Nobbenhuis MA, Walboomers JM, Heimerhorst TJ, et al. Relation of human papillomavirus status to cervical consequences for cervical-cancer screening: A prospective study. Lancet 1999, 354, 20-25.
5. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992, 327, 1272-1278.
6. Franceschi S, Clifford G, Plummer M. Prospects for primary prevention of cervical cancer in developing countries. Salud Publica Mex 2003, 45, S430-S436.
7. Frazer I. Vaccines for papillomavirus infection. Virus Res 2002, 89, 271-274.
8. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002, 347, 1645-1651.
9. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993, 53, 3579-3584.
10. Grandis JR, Tweardy DJ, Melhem MF. Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin Cancer Res 1998, 4, 13-20.
11. Kurie JM, Shin HJ, Lee JS, et al. Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res 1996, 2, 1787-1793.
12. Kim H, Muller WJ. The role of the epidermal growth factor receptor family in mammary tumourigenesis and metastasis. Exp Cell Res 1999, 253, 78-87.
13. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001, 37(Suppl. 4), S9-S15.
14. Mendelsohn J, Fan Z. Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst 1997, 89, 341-343.
15. Corvo R, Antognoni P, Sanguineti G. Biological predictors of response to radiotherapy in head and neck cancer: Recent advances and emerging perspectives. Tumouri 2001, 87, 355-363.
16. Khuri FR. Primary and secondary prevention of non-small-cell lung cancer: the SPORE Trials of Lung Cancer Prevention. Clin Lung Cancer 2003, 5(Suppl. 1), S36-S40.
17. Yuand D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 2000, 19, 6115-6121.
18. Gullick WJ, Love SB, Wright C, et al. C-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 1991, 63, 434-438.
19. Stark A, Hulka BS, Joens S, et al. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. J Clin Oncol 2000, 18, 267-274.
20. Vogelstein B. Genetic alterations during colorectal-tumour development. N EnglJ Med 1988, 319, 525-532.
21. Nagasaka T. Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol 2004, 22, 4584-4594.
22. Rajagopolan H. Tumourigenesis: Raf/Ras oncogenes and mismatch-repair status. Nature 2002, 418, 934.
23. Herrera R, Sebolt-Leopold JS. Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention. Trends Mol Med 2002, 8(Suppl. 4), S27-S31.
24. Bollag G, Freeman S, Lyons JF, et al. Raf Pathway inhibitors in oncology. Curr Opin Investig Drugs 2003, 12, 1436-1441.
25. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumour activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis. Cancer Res 2004, 64, 7099-7109.
26. Alessi DR, Andelkovic M, Caudwell B, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996, 15, 6541-6551.
27. Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumour suppressor PTEN. Cell 1998, 95, 29-39.
28. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275, 1943-1947.
29. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMACl, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997, 15, 356-362.
30. Li DM, Sun H. TEP1, encoded by a candidate tumour suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 1997, 57, 2124-2129.
31. Di Cristofano A, Pesce B, Cordon-Cardo C, et al. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998, 19, 348-355.
32. Ali IU, Schriml LM, Dean M. Mutational spectra of PTEN/MMAC1 gene: a tumour suppressor with lipid phosphatase activity. J Natl Cancer Inst 1999, 91, 1922-1932.
33. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumour suppression. Cell 2000, 100, 387-390.
34. Trotman LC, Niki M, Dotan Z, et al. Pten dose dictates cancer progression. PLoS Biol 2003, 1(3), E59.
35. Maxwell GL, Risinger JI, Gumbs C, et al. Mutation of the PTEN tumour suppressor gene in endometrial hyperplasias. Cancer Res 1998, 58, 2500-2503.
36. Levine RL, Cargile CB, Blazes MS, et al. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res 1998, 58, 3254-3258.
37. Goell A, Arnold CN, Niedzwiecki D, et al. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability -high sporadic colorectal cancers. Cancer Res 2004, 64, 3014-3021.
38. Chan TO, Rittenhouse SE, Tsichlis PN. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phos-phoinositide- dependent phosphorylation. Annu Rev Biochem 1999, 68, 965-1014.
39. Krystal GW, Sulanke G, Litz J. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Therapeut 2002, 1, 913-922.
40. Sun M, Paciga JE, Feldman RI, et al. Phosphatidylinositol-3-OH kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor (ER) via interaction between ER and PI3K. Cancer Res 2001, 61, 5985-5991.
41. Bose S, Crane A, Hibshoosh H, et al. Reduced expression of PTEN correlates with breast cancer progression. Hum Pathol 2002, 33, 405-409.
42. Clark AS, West K, Streicher S, et al. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002, 1, 707-717.
43. Amornphimoltham P, Sriuranpong V, Patel V, et al. Persistent activation of the Akt pathway in head and neck squamous cell carcinoma. Clin Cancer Res 2004, 10, 4029-4037.
44. Aoki M, Blazek E, Vogt PK. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci USA 2001, 98, 136-141.
45. Andre C, Martin E, Cornu M, et al. Genomic organization of the human c-kit gene: Evolution of the receptor tyrosine kinase subclass III. Oncogene 1992, 7, 685-691.
46. Spritz RA, Strunk KM, Lee S-T, et al. A YAC contig spanning a cluster of human type III receptor protein tyrosine kinase genes (PDGFRA-KIT-KDR) in chromosome segment 4q12. Genomics 1994, 22, 431-436.
47. Qiu F, Ray P, Brown K, et al. Primary structure of c-kit: Relationship with the CSF-1/PDGF receptor kinase family. EMBOJ 1988, 4, 1003-1011.
48. Herbst R, Munemitsu S, Ullrich A. Oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO J 1988, 7, 1003-1011.
49. Geissler EN, Liao M, Brook JD, et al. Stem cell factor (SCF), a novel hematopoietic growth factor and ligand for c-kit tyrosine kinase receptor, maps on human chromosome 12 between 12ql4.3 and l2qter. Somat Cell Mol Genet 1991, 17, 207-214.
50. Heinrich MC, Blanke CD, Druker BJ, et al. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002, 20, 1692-1703.
51. Isozaki K, Terris B, Belghiti J, et al. Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumours. Am J Pathol 2000, 157, 1581-1585.
52. Nishida T, Hirota S, Taniguchi M, et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet 1998, 19, 323-324.
53. Maeyama H, Hidaka E, Ota H, et al. Familial gastrointestinal stromal tumour with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology 2001, 120, 210-215.
54. Eilber FC, Rosen G, Forscher C, et al. Recurrent gastrointestinal stromal sarcomas. Surg Oncol 2000, 9, 71-75.
55. Kemmer K, Corless CL, Fletcher JA, et al. KIT mutations are common in testicular seminomas. Am J Pathol 2004, 164, 305-313.
56. Senderowicz AM. Novel small molecule cyclin-dependent kinases modulators in human clinical trials. Cancer Biol Ther 2003, 2, S84-S95.
57. Lonardo F, Rusch V, Langenfeld J, et al. Overexpression of cyclins Dl and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development. Cancer Res 1999, 59, 2470-2476.
58. Schauer IE, Siriwardana S, Langan TA, et al. Cyclin D1 Overexpression vs. retinoblastoma inactivation: implications for growth control evasion in non-small cell and small cell lung cancer. Proc Natl Acad Sci USA 1994, 91, 7827-7831.
59. Hayashi H, Ogawa N, Ishiwa N, et al. High cyclin E and low p27/Kip1 expressions are potentially poor prognostic factors in lung adenocarcinoma patients. Lung Cancer 2001, 34, 59-65.
60. Lonardo F, Dragnev KH, Freemantle SJ, et al. Evidence for the epidermal growth factor receptor as a target for lung cancer prevention, Clin Cancer Res 2002, 8, 54-60.
61. Horowitz JM, Park SH, Bogenmann E, et al. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumour cells. Proc Natl Acad Sci USA 1990, 87, 2775-2779.
62. Wadayama B, Toguchida J, Shimizu T, et al. Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res 1994, 54, 3042-3048.
63. Hensel CH, Hsieh L, Gazdar AF, et al. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res 1990, 50, 3067-3072.
64. Huang HJ, Yee JK, Shew JY, et al. Suppression of the neoplastic phenotype by replacement of the retinoblastoma gene product in human cancer cells. Science (Washington, DC) 1988, 242, 1563-1566.
65. Hensel CH, Hsieh CL, Gazdar Af, et al. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res 1990, 10, 3067-3072.
66. Baldi A, Esposito V, De Luca A, et al. Differential expression of the retinoblastoma gene family members, Rb, p107 and Rb2/p130 in lung cancer. Clin Cancer Res 1996, 7, 1239-1245.
67. Baldi A, Esposito V, De Luca A, et al. Differential expression of Rb2/p130 and p107 in normal human tissues and in primary lung cancer. Clin Cancer Res 1997, 3, 1691-1697.
68. Hollstein M, Rice K, Greenblatt MS, et al. Database of p53 gene somatic mutations in human tumours and cell lines. Nucleic Acids Res 1994, 22, 3551-3555.
69. Vahakangas KH, Samet JM, Metcalf RA, et al. Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet 1992, 339, 576-580.
70. Sozzi G, Miozzo M, Donghi R, et al. Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res 1992, 52, 6079-6082.
71. Sundaresan V, Ganly P, Hasleton P, et al. p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus. Oncogene 1992, 7, 1989-1997.
72. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996, 87, 159-170.
73. Fearon ER, Vogelstein B. A genetic model for colorectal tumourigenesis. Cell 1990, 61, 759-767.
74. Shin DM, Xu XC, Lippman SM, et al. Accumulation of p53 protein and retinoic acid receptor in retinoid chemoprevention. Clin Cancer Res 1997, 3, 875-880.
75. Sidransky D, Messing E. Molecular genetics and biochemical mechanisms in bladder cancer. Oncogenes, tumour suppressor genes, and growth factors. Urol Clin North Am 1992, 19, 629-639.
76. Mao L, Schoenberg MP, Scicchitano M, et al. Molecular detection of primary bladder cancer by microsatellite analysis. Science (Washington, DC) 1996, 271, 659-662.
77. Grossman HB, Schmitz-Drager B, Fradet Y, et al. Use of markers in defining urothelial premalignant and malignant conditions. Scand J Urol Nephrol 2000, 205(Suppl.), 94-104.
78. Rudin CM, Cohen EE, Papadimitrakopoulou VA, et al. An attenuated adenovirus, ONYX 015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol 2003, 21, 4546-4552.
79. Clayman GL, el-Naggar AK, Lippman SM, et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998, 16, 2221-2232.
80. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999, 13, 1899-1911.
81. Reed JC. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am 1995, 9, 451-473.
82. Minn AJ, Rudin CM, Boise LH, et al. Expression of bcl-xL can confer a multidrug resistance phenotype. Blood 1995, 86, 1903-1910.
83. Zhang GJ, Kimijima I, Tsuchiya A, et al. The role of bcl-2 expression in breast carcinomas Review. Oncol Rep 1998, 5, 1211-1216.
84. Laudanski J, Chyczewski L, Niklinska WE, et al. Expression of bcl-2 protein in non-small cell lung cancer: Correlation with clinicopathology and patient survival. Neoplasma 1999, 46, 25-30.
85. Bubendorf L, Sauter G, Moch H, et al. Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am J Pathol 1996, 148, 1557-1565.
86. Viale G, Roncalli M, Grimelius L, et al. Prognostic value of bcl-2 immunoreactivity in medullary thyroid carcinoma. Hum Pathol 1995, 26, 945-950.
87. Aizawa K, Ueki K, Suzuki S, et al. Apoptosis and bcl-2 expression in gastric carcinomas: Correlation with clinicopathological variables, p53 expression, cell proliferation and prognosis. Int J Oncol 1999, 14, 85-91.
88. Kong G, Shin KY, Oh YH, et al. Bcl-2 and p53 expressions in invasive bladder cancers. Acta Oncol 1998, 37, 715-720.
89. Herod JJ, Eliopoulos AG, Warwick J, et al. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 1996, 56, 2178-2184.
90. Crawford RA, Caldwell C, Iles RK, et al. Prognostic significance of the bcl-2 apoptotic family of proteins in primary and recurrent cervical cancer, Br J Cancer 1998, 78, 210-214.
91. Grover R, Wilson GD. Bcl-2 expression in malignant melanoma, and its prognostic significance. Eur J Surg Oncol 1996, 22, 347-349.
92. Gasparini G, Bevilacqua P, Bonoldi E, et al. Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy. Clin Cancer Res 1995, 1, 1375-1383.
93. Wilson GD, Grover R, Richman PI, et al. Bcl-2 expression correlates with favourable outcome in head and neck cancer treated by accelerated radiotherapy. Anticancer Res 1996, 16, 2403-2408.
94. Gallo O, Boddi V, Calzolari A, et al. bcl-2 protein expression correlates with recurrence, and survival in early stage head, and neck cancer treated by radiotherapy. Clin Cancer Res 1996, 2, 261-267.
95. Pena JC, Thompson CB, Recant W, et al. Bcl-xL, and Bcl-2 expression in squamous cell carcinoma of the head, and neck. Cancer 1999, 85, 164-170.
96. Friedman M, Grey P, Venkatesan TK, et al. Prognostic significance of Bcl-2 expression in localized squamous cell carcinoma of the head and neck. Ann Otol Rhinol Laryngol 1997, 106, 445-450.
97. Lu QL, Abel P, Foster CS, et al. bcl-2 role in epithelial differentiation and oncogenesis. Hum Pathol 1996, 27, 102-110.
98. Jordan RC, Catzavelos GC, Barrett AW, et al. Differential expression of bcl-2 and bax in squamous cell carcinomas of the oral cavity. Eur J Cancer B Oral Oncol 1996, 32B, 394-400.
99. Birchall MA, Schock E, Harmon BV, et al. Apoptosis, mitosis, PCNA, and bcl-2 in normal, leukoplakic, and malignant epithelia of the human oral cavity, prospective, in vivo study. Oral Oncol 1997, 33, 419-425.
100. Singh BB, Chandler Jr FW, Whitaker SB, et al. Immunohistochemical evaluation of bcl-2 oncoprotein in oral dysplasia and carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998, 85, 692-698.
101. Baretto GB, Diebold J, Christoforis G, et al. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas: Aspects of carcinogenesis and prognostic significance. Cancer 1998, 77, 2255-2264.
102. Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000, 52, 237-268.
103. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002, 2, 795-803.
104. Carmeliet P, Jain Rk. Angiogenesis in cancer and other diseases. Nature 2000, 407, 249-257.
105. Risau W. Mechanism of angiogenesis. Nature 1997, 386, 671-674.
106. Filder IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003, 3, 453-458.
107. Yu JL, Rak JW, Coomber BL, et al. Effect of p53 status on tumour response to antiangiogenic therapy. Science 2002, 295, 1526-1528.
108. Garkavtsev I, Kozin SV, Chernova O, et al. The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 2004, 428, 328-332.
109. Tae K, El-Naggar AK, Yoo E, et al. Expression of vascular endothelial growth factor and microvessel density in head and neck tumourigenesis. Clin Cancer Res 2000, 6, 2821-2828.
110. Shin DM, Kim JG, Ro JY, et al. Activation of p53 gene in premalignant lesions during head and neck tumourigenesis. Cancer Res 1994, 54, 321-326.
111. Aotake T, Lu CD, Chiba Y, et al. Changes of angiogenesis and tumour cell apoptosis during colorectal carcinogenesis. Clin Cancer Res 1999, 5, 135-142.
112. Dazzi C, Cariello A, Maioli P, et al. Prognostic and predictive value of intratumoural microvessels density in operable non-small-cell lung cancer. Lung Cancer 1999, 24, 81-88.
113. Fontanini G, Calcinai A, Boldrini L, et al. Modulation of neoangiogenesis in bronchial preneoplastic lesions. Oncol Rep 1999, 6, 813-817.
114. Maatta M, Santala M, Soini Y, et al. Matrix metalloproteinases 2 and 9 and their tissue inhibitors in low malignant potential ovarian tumours. Tumour Biol 2004, 4, 188-192.
115. Xie M, Sun Y, Li Y. Expression of matrix metalloproteinases in supraglottic carcinoma and its clinical implication for estimating lymph node metastases. Laryngoscope 2004, 114, 2243-2248.
116. Pellikainen JM, Ropponen KM, Kataja VV, et al. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 2004, 22, 7621-7628.
117. Nelson AR, Fingleton B, Rothenberg M, et al. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000, 5, 1135-1149.
118. McDonnell S, Matrisian LM. Stromelysin in tumour progression and invasion. Cancer Metast Rev 1991, 9, 305-319.
119. MacDougall JR, Bani MR, Lin Y, et al. The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: Suppression by somatic cell hybridization with early stage melanoma cell. Cancer Res 1995, 55, 4174-4181.
120. Vaisanen A, Tuominen H, Kallioinen M, et al. Matrix metalloproteinase-2 (72 kd type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. Pathology 1996, 180, 283-289.
121. Newell KJ, Witty JP, Rodgers WH, et al. Expression and localization of matrix-degrading metalloproteinases during colorectal tumourigenesis. Mol Carcinog 1994, 10, 199-206.
122. Zeng ZS, Cohen AM, Guillem JG. Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumourigenesis. Carcinogenesis 1999, 20, 749-755.
123. Sreedhar AS, Stöi C, Csermely P. Inhibition of Hsp90: a new strategy for inhibiting protein kinases. Biochim Biophys Acta 2004, 1697, 233-242.
124. Caplan AJ. Hsp90's secrets unfold: new insights from structural and functional studies. Trends Cell Biol 1999, 9, 262-268.
125. Rutherford SL, Lindquist S. Hsp90 as a capacitor for morphological evolution. Nature 1998, 396, 336-342.
126. Akalin A, Elmore LW, Forsythe HL, et al. A novel mechanism for chaperone-mediated telomerase regulation during prostate cancer progression. Cancer Res 2001, 61, 4791-4796.
127. Cardillo MR, Sale P, Di Silverio F. Heat shock protein-90, IL-6 and IL-1O in bladder cancer. Anticancer Res 2000, 20, 4579-4583.
128. Hermisson M, Strik H, Rieger J, et al. Expression and functional activity of heat shock proteins in human glioblastoma multiforme. Neurology 2000, 54, 1357-1365.
129. Ito T, Kawabe R, Kurasono Y, et al. Expression of heat shock proteins in squamous cell carcinoma of the tongue: an immunohistochemical study. J Oral Pathol Med 1998, 27, 18-22.
130. Nanbu K, Konishi I, Komatsu T, et al. Expression of heat shock proteins HSP70 and HSP90 in endometrial carcinomas. Correlation with clinicopathology, sex steroid receptor status, and p53 protein expression. Cancer 1996, 77, 330-338.
131. Ogata M, Naito Z, Tanaka S, et al. Overexpression and localization of heat shock proteins mRNA in pancreatic carcinoma. J Nippon Med Sch 2000, 67, 177-185.
132. Yano M, Naito Z, Tanaka S, et al. Expression and roles of heat shock proteins in human breast cancer. Jpn J Cancer Res 1996, 87, 908-915.
133. Yano M, Naito Z, Yokoyama M, et al. Expression of hsp90 and cyclin D1 in human breast cancer. Cancer Lett 1999, 137, 45-51.
134. Blagosklonny MV, Fojo T, Bhalla KN, et al. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Ab1-expressing leukemia cells to cytotoxic chemotherapy. Leukemia 2001, 15, 1537-1543.
135. Sreedhar AS, Söti C, Csermely P. Inhibition of Hsp90: a new strategy for inhibiting protein kinases. Biochim Biophys Acta 2004, 1697, 233-242.
136. Ramsahoye BH, Biniszkiewicz D, Lyko F, et al. Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. Proc Natl Acad Sci USA 2000, 97, 5237-5242.
137. Feinberg AP. Cancer epigenetics takes center stage. Proc Natl Acad Sci USA 2001, 98, 392-394.
138. Cui H, Niemitz EL, Ravenel JD, et al. Loss of imprinting of insulin-like growth factor-II in Wilms' tumour commonly involves altered methylation but not mutations of CTCF or its binding site. Cancer Res 2001, 61, 4947-4950.
139. Herman JG, Baylin SB. Promoter-region hypermethylation and gene silencing in human cancer. Curr Top Microbiol Immunol 2000, 249, 35-54.
140. Esteller M, Risques RA, Toyota M, et al. Promoter hypermethylation of the DNA repair gene O (6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumourigenesis. Cancer Res 2001, 61, 4689-4692.
141. Rhee I, Bachman KE, Park BH, et al. DNMTl and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002, 416, 552-556.
142. De Smet C, De Backer O, Faraoni I, et al. The activation of human gene MAGE-1 in tumour cells is correlated with genomewide demethylation. Proc Natl Acad Sci USA 1996, 93, 7149-7153.
143. De Smet C, Lurquin C, Lethe B, et al. DNA methylation is the primary silencing mechanism for a set of germ line- and tumour-specific genes with a CpG-rich promoter. Mol Cell Biol 1999, 19, 7327-7335.
144. Das Partha M, Singal Rakesh. DNA methylation and cancer. J Clin. Oncol. 2004, 22, 4632-4642.
145. Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of p16ink4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998, 95, 11891-11896.
146. Tang X, Khuri FR, Lee JJ, et al. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst (Bethesda) 2000, 92, 1511-1516.
147. Esteller M, Corn PG, Urena JM, et al. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res 1998, 58, 4515-4518.
148. Soria JC, Rodriguez M, Liu DD, et al. Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. Cancer Res 2002, 62, 351-355.
149. Youssef EM, Lotan D, Issa JP, et al. Hypermethylation of the retinoic acid receptor-2 gene in head and neck carcinogenesis. Clin Cancer Res 2004, 10, 1733-1742.
150. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev 2003, 29, 3-9.
151. Simons M, Keller P, Dichgans J, et al. Cholesterol and Alzheimer's disease: is there a link. Neurology 2001, 57, 1089-1093.
152. Jick H, Zornber GL, Jick SS, et al. Statins and the risk of dementia. Lancet 2000, 356, 1627-1631.
153. Wolozin B, Kellman W, Ruosseau P, et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitors. Arch Neurol 2000, 57, 1439-1443.
154. Coons JC. Hydroxymethylglutaryl-coenzyme A reductase inhibitors in osteoporosis management. Ann Pharmacother 2002, 36, 326-330.
155. Graaf MR, Richel DJ, van Norden CJF, et al. Effects of statin and farnesyltarnsferase inhibitors on the development and progression of cancer. Cancer Treat Rev 2004, 30, 609-641.
156. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998, 279, 1615-1622.
157. Pedersen TR, Wilhelmsen L, Faergeman O, et al. Follow-up study of patients randomized in the Scandinavian simvastatin-survival study (4S) of cholesterol lowering. Am J Cardiol 2000, 86, 257-262.
158. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335, 1001-1009.
159. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339, 1349-1357.
160. Khuri FR, Cohen V. Molecularly targeted approaches to the chemoprevention of lung cancer. Clin Cancer Res 2004, 10, 4249S-4253S.
161. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994, 330, 1029-1035.
162. Ommen GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996, 334, 1150-1155.